HIGH

Biocon Prazosin Hydrochloride 2 mg Capsules Recalled for Nitrosamine Impurity (58,896 bottles, 2026)

Biocon Pharma Inc. recalled 58,896 bottles of Prazosin Hydrochloride Capsules, USP, 2 mg, 100-count bottle. The product was distributed nationwide in the USA and manufactured by Appco Pharma LLC. A cGMP deviation detected N-nitroso-prazosin impurity C above acceptable limits. Consumers and healthcare providers should stop using this product immediately and contact Appco Pharma LLC or their health‑

Quick Facts at a Glance

Recall Date
March 27, 2026
Hazard Level
HIGH
Brands
Prazosin Hydrochloride, Biocon Pharma
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Appco Pharma LLC or your healthcare provider for guidance. Notification method: E-Mail

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Prazosin hydrochloride is a prescription antihypertensive and symptom-management drug. This recall concerns specific lots produced for Biocon Pharma and distributed nationwide in the United States.

Why This Is Dangerous

Nitrosamine impurities in drug substances may pose long-term cancer risk. The impurity detected is N-nitroso-prazosin impurity C (NNP) above acceptable limits due to a cGMP deviation.

Industry Context

This recall is not stated as part of a broader industry pattern.

Real-World Impact

Patients using the recalled lots should stop taking the medication and consult their clinician. The recall affects a limited number of bottles but requires action to avoid potential long-term risk.

Practical Guidance

How to identify if yours is affected

  1. Verify NDC 70377-067-11 on the bottle label.
  2. Check lot numbers: 2404153UC, 2404154UC, 2502055UC, 2505173UC, 2505175UC.
  3. Check expiration dates: 2026 MAR for the first two lots; 2027 JAN and 2027 MAY for the latter lots.
  4. Confirm bottle description: Prazosin Hydrochloride Capsules, USP, 2 mg, 100-count bottle.

Where to find product info

FDA recall page for D-0420-2026 and the enforcement report linked there.

What timeline to expect

No specific refund or replacement timeline is provided in the recall notice.

If the manufacturer is unresponsive

  • Document all correspondence with Appco Pharma LLC and your healthcare provider.
  • If the company is slow to respond, contact your pharmacist or physician for guidance.
  • Report any adverse events to the FDA MedWatch program.

How to prevent similar issues

  • Only obtain prescription medications from licensed pharmacies.
  • Always verify NDC numbers before dispensing medicines.
  • Keep medication packaging intact to preserve recall references.
  • Talk to your healthcare provider about alternatives if you require ongoing treatment.

Documentation advice

Keep the bottle, packaging, lot numbers, expiration dates, and all correspondence with the manufacturer or healthcare providers.

Product Details

Model numbers and lot information below are associated with this recall. NDC 70377-067-11. 58,896 bottles recalled. 100-count bottle. Sold in the USA nationwide. Manufactured for Biocon Pharma Inc., Iselin, NJ. Manufactured by Appco Pharma LLC, Piscataway, NJ.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 58,896 bottles recalled
  • NDC 70377-067-11
  • Lot 2404153UC Exp 2026/MAR
  • Lot 2404154UC Exp 2026/MAR
  • Lot 2502055UC Exp 2027/JAN
  • Lot 2505173UC Exp 2027/MAY 2505175UC Exp 2027/MAY

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
7/ 10
Affected Groups
GENERAL
Injury Types
POISONINGOTHER

Product Details

Model Numbers
Lot 2404153UC
Exp 2026/MAR
Lot 2404154UC
Exp 2026/MAR
Lot 2502055UC
+5 more
UPC Codes
70377-066
70377-067
70377-068
+3 more
Affected States
ALL
Report Date
April 8, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more